New hope for tough pancreatic cancer: trial tests Immune-Boosting combo
NCT ID NCT06904378
Summary
This study is testing a new drug called ONT01 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with metastatic pancreatic cancer that has worsened after their first treatment. The goal is to see if this combination can better control the cancer by changing the environment around the tumor to help the body's defenses. Researchers will first find the safest dose and then see how well it works at stopping cancer growth for at least 6 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.